CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Conditions: Pancreatic Cancer
Interventions: Drug: CPI 613; Drug: Oxaliplatin; Drug: Irinotecan; Drug: 5-flurouracil; Drug: Folinic acid
Sponsors: David Bajor
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

January 30, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments